Exact Mass: 429.2064

Exact Mass Matches: 429.2064

Found 500 metabolites which its exact mass value is equals to given mass value 429.2064, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

7-Benzylidenenaltrexone

C27H27NO4 (429.194)

D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists

Abiraterone sulfate

[(8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulate

C24H31NO4S (429.1974)

Abiraterone sulfate is a metabolite of abiraterone. Abiraterone is a drug used in castration-resistant prostate cancer (formerly hormone-resistant or hormone-refractory prostate cancer) (prostate cancer not responding to androgen deprivation or treatment with antiandrogens). It is formulated as the prodrug abiraterone acetate and marketed under the trade name Zytiga. After an expedited six-month review, abiraterone was approved by the U.S. Food and Drug Administration (FDA) in April 2011. (Wikipedia)

7-Benzylidenenaltrexone

4-(cyclopropylmethyl)-10,17-dihydroxy-15-(phenylmethylidene)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one

C27H27NO4 (429.194)

Guan-fu base A

3-(acetyloxy)-9,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0^{1,8}.0^{5,17}.0^{7,16}.0^{9,14}.0^{14,18}]nonadecan-10-yl acetate

C24H31NO6 (429.2151)

Guanfu base A is an antiarrhythmic alkaloid isolated from Aconitum coreanum and is a potent noncompetitive CYP2D6 inhibitor, with a Ki of 1.20 μM in human liver microsomes (HLMs) and a Ki of 0.37 μM for the human recombinant form (rCYP2D6). Guanfu base A is also a potent competitive inhibitor of CYP2D in monkey (Ki of 0.38 μM) and dog (Ki of 2.4 μM) microsomes[1]. Guanfu base A also inhibits HERG channel current[2]. Guanfu base A is an antiarrhythmic alkaloid isolated from Aconitum coreanum and is a potent noncompetitive CYP2D6 inhibitor, with a Ki of 1.20 μM in human liver microsomes (HLMs) and a Ki of 0.37 μM for the human recombinant form (rCYP2D6). Guanfu base A is also a potent competitive inhibitor of CYP2D in monkey (Ki of 0.38 μM) and dog (Ki of 2.4 μM) microsomes[1]. Guanfu base A also inhibits HERG channel current[2].

Hippuryl-histidyl-leucine

2-[[2-[(2-benzamidoacetyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid

C21H27N5O5 (429.2012)

2-(2-(4-Phenoxy-2-propylphenoxy)ethyl)indole-5-acetic acid

2-{2-[2-(4-phenoxy-2-propylphenoxy)ethyl]-1H-indol-5-yl}acetic acid

C27H27NO4 (429.194)

Sarpogrelate

mono-(2-(dimethylamino)-1-((2-(2-(3-Methoxyphenyl)ethyl)phenoxy)methyl)ethyl)succinate hydrochloride

C24H31NO6 (429.2151)

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents

relative retention time with respect to 9-anthracene Carboxylic Acid is 1.163 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.170

2-amino-3-[[(6E,9E)-5-hydroxy-8-methoxy-5,9,13,14-tetramethyl-2-oxo-1-oxacyclotetradeca-6,9-dien-4-yl]sulfanyl]propanoic acid

C21H35NO6S (429.2185)

MMV023949

C24H27N7O (429.2277)

(-)-trans-2-fluorocyclohexyl-N-[p-(4-methyl-beta-D-glucopyranosyl)]phenyl-carbamate

C20H28FNO8 (429.1799)

C24H31NO6

C24H31NO6 (429.2151)

(-)N-(12-Acetoxy)jasmonoyl-phenylalaninmethylester

C24H31NO6 (429.2151)

guan-fu base A1

C24H31NO6 (429.2151)

Apiosporamide